MCID: OLG002
MIFTS: 59

Oligodendroglioma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Oligodendroglioma

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 12 53 59 29 55 6 44 15 73
Oligodendroglial Neoplasm 12 73
Well Differentiated Oligodendroglioma 73
Oligodendroglial Tumors 55
Oligodendroglial Tumor 12

Characteristics:

Orphanet epidemiological data:

59
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 44 D009837
NCIt 50 C6960
Orphanet 59 ORPHA251627
UMLS via Orphanet 74 C0028945
ICD10 via Orphanet 34 C71.9

Summaries for Oligodendroglioma

NIH Rare Diseases : 53 Oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. They can be low-grade (grade II) or high-grade (grade III, also called anaplastic). While they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. They are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. They tend to grow slowly and may be present for many years before they are diagnosed. Common symptoms include seizures, headaches and changes in personality. Other symptoms vary by the size and location of the tumor. The exact cause of opigodendrogliomas is unknown. Some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. Treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy. Recurrent tumors may need additional surgery, radiation and chemotherapy.

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to adult oligodendroglioma and childhood oligodendroglioma. An important gene associated with Oligodendroglioma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Carmustine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and temporal lobe, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
# Related Disease Score Top Affiliating Genes
1 adult oligodendroglioma 34.8 IDH1 IDH2
2 childhood oligodendroglioma 34.1 GFAP IDH1 OLIG2 SYP TP73
3 oligoastrocytoma 34.0 GFAP IDH2 MGMT
4 glioma susceptibility 1 34.0 IDH1 IDH2 TP53
5 anaplastic oligodendroglioma 32.8 CDKN2A CDKN2C EGFR GFAP IDH2 MGMT
6 dysembryoplastic neuroepithelial tumor 31.6 GFAP IDH1 SYP
7 extraventricular neurocytoma 31.3 GFAP IDH1 SYP
8 central neurocytoma 31.2 ENO2 GFAP SYP
9 gemistocytic astrocytoma 30.9 GFAP IDH2 PTEN
10 gangliocytoma 30.9 GFAP PTEN SYP
11 angiocentric glioma 30.9 GFAP IDH1 SYP
12 teratoma 30.8 ENO2 GFAP SYP TP53
13 astroblastoma 30.7 ENO2 GFAP SYP
14 cystic teratoma 30.5 ENO2 GFAP SYP TP53
15 glioma 30.4 CDKN2A EGFR IDH1 IDH2 PDGFRA POT1
16 ependymoma 30.3 EGFR ENO2 GFAP MGMT SYP TP73
17 ganglioglioma 30.3 ENO2 GFAP SYP TP53
18 clear cell ependymoma 30.1 ENO2 GFAP OLIG2 SYP TP53
19 myeloma, multiple 30.1 CDKN2A IDH1 IDH2 TP53
20 pleomorphic xanthoastrocytoma 30.1 GFAP IDH1 MGMT SYP TP53
21 mixed glioma 29.9 GFAP IDH1 PDGFRA TP53
22 cerebellar liponeurocytoma 29.8 ENO2 GFAP OLIG2 SYP TP53
23 neurilemmoma 29.8 ENO2 GFAP PDGFRA
24 juvenile pilocytic astrocytoma 29.7 CDKN2A ENO2 GFAP MBP TP53
25 pilocytic astrocytoma 29.5 CDKN2A GFAP IDH1 MGMT OLIG2 PTEN
26 hydrocephalus 29.4 ENO2 GFAP MBP PTEN SYP TP53
27 gliosarcoma 29.3 EGFR ENO2 GFAP IDH1 MGMT PTEN
28 glioblastoma multiforme 28.1 CDKN2A EGFR GFAP IDH1 MGMT PDGFRA
29 glioblastoma 27.6 CDKN2A CDKN2B EGFR IDH1 IDH2 MGMT
30 brain cancer 26.3 EGFR ENO2 GFAP IDH1 IDH2 MGMT
31 medulloblastoma 26.1 CDKN2B EGFR ENO2 GFAP IDH1 MGMT
32 grade iii astrocytoma 25.6 CDKN2A CDKN2B EGFR GFAP IDH2 MGMT
33 spinal cord oligodendroglioma 12.1
34 corpus callosum oligodendroglioma 12.1
35 brain oligodendroglioma 12.1
36 mixed oligodendroglioma-astrocytoma 12.1
37 mixed astrocytoma-ependymoma-oligodendroglioma 11.9
38 interval angle-closure glaucoma 11.1 IDH1 IDH2
39 enchondroma 11.1 IDH1 IDH2
40 desmoplastic infantile ganglioglioma 11.0 GFAP SYP
41 adult astrocytic tumour 11.0 IDH1 IDH2 PTEN
42 lung combined type small cell carcinoma 11.0 GFAP SYP
43 periosteal chondrosarcoma 11.0 CDKN2A IDH1 IDH2
44 vulvar dystrophy 11.0 CDKN2A MBP
45 ureter small cell carcinoma 10.9 ENO2 SYP
46 anaplastic ependymoma 10.9 GFAP PTEN SYP
47 breast papillary carcinoma 10.9 IDH1 IDH2 SYP
48 cerebellopontine angle tumor 10.9 GFAP IDH1 SYP
49 malignant sertoli cell tumor 10.9 ENO2 SYP
50 urinary bladder small cell neuroendocrine carcinoma 10.9 ENO2 SYP

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.98 EGFR
2 Decreased viability GR00173-A 9.98 PDGFRA
3 Decreased viability GR00221-A-1 9.98 POT1 CDKN2A CDKN2C EGFR PDGFRA
4 Decreased viability GR00221-A-3 9.98 PDGFRA POT1 CDKN2A
5 Decreased viability GR00221-A-4 9.98 PDGFRA POT1 CDKN2A EGFR
6 Decreased viability GR00301-A 9.98 CDKN2C
7 Decreased viability GR00342-S-2 9.98 CDKN2C
8 Decreased viability GR00402-S-2 9.98 POT1 CDKN2A CDKN2C EGFR PDGFRA
9 Decreased viability in esophageal squamous lineage GR00235-A 9.36 POT1 CDKN2A PTEN TP53 CDKN2C GFAP

MGI Mouse Phenotypes related to Oligodendroglioma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 ENO2 CDKN2C CDKN2A EGFR CDKN2B GFAP
2 growth/size/body region MP:0005378 10.39 ENO2 CDKN2C CDKN2A EGFR GFAP NKX2-2
3 behavior/neurological MP:0005386 10.37 CDKN2C CDKN2A ENO2 GFAP OLIG1 MBP
4 mortality/aging MP:0010768 10.36 CDKN2C CDKN2A EGFR CDKN2B PDGFRA MGMT
5 homeostasis/metabolism MP:0005376 10.34 CDKN2C CDKN2A EGFR CDKN2B MGMT NKX2-2
6 immune system MP:0005387 10.26 CDKN2C CDKN2A EGFR CDKN2B GFAP IDH1
7 nervous system MP:0003631 10.24 ENO2 CDKN2C CDKN2A EGFR PDGFRA GFAP
8 endocrine/exocrine gland MP:0005379 10.22 CDKN2C CDKN2A EGFR CDKN2B MGMT NKX2-2
9 embryo MP:0005380 10.14 CDKN2A EGFR NKX2-2 PTEN PDGFRA POT1
10 neoplasm MP:0002006 10.14 CDKN2C CDKN2A EGFR CDKN2B PDGFRA MGMT
11 integument MP:0010771 10.06 CDKN2B CDKN2C CDKN2A EGFR OLIG1 PTEN
12 no phenotypic analysis MP:0003012 9.92 CDKN2B CDKN2A EGFR MGMT OLIG2 PDGFRA
13 reproductive system MP:0005389 9.85 CDKN2C CDKN2A EGFR CDKN2B NKX2-2 MBP
14 respiratory system MP:0005388 9.7 ENO2 CDKN2C CDKN2A EGFR MGMT PDGFRA
15 pigmentation MP:0001186 9.65 CDKN2A EGFR PTEN PDGFRA TP53
16 vision/eye MP:0005391 9.23 CDKN2A EGFR GFAP OLIG2 MBP PTEN

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 360)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
9
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
10
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
11
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
12
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
13
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
17
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
20
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
21
Dopamine Approved Phase 3,Not Applicable 51-61-6, 62-31-7 681
22
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
23
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
27 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
28 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
32 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
34 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
36 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
37 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
41 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
42 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
43 Liver Extracts Phase 3,Phase 2,Phase 1
44 Keratolytic Agents Phase 3,Phase 1,Phase 2
45 Adjuvants, Anesthesia Phase 3
46 Analgesics Phase 3,Phase 2,Phase 1
47 Analgesics, Opioid Phase 3
48 Anesthetics Phase 3,Phase 1
49 Anesthetics, General Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 370)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
5 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
7 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
8 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
11 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
12 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
13 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
14 gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
15 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
16 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
17 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
18 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
19 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
20 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
21 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
22 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
23 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
24 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
25 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
26 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
27 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
28 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
29 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
30 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
31 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
32 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
33 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
34 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
35 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
36 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
37 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
38 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
39 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
40 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
41 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 RAD001
42 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
43 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
44 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2 temozolomide
45 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
46 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
47 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
48 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed NCT00575887 Phase 2 Temozolomide
49 The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) Completed NCT00392171 Phase 2 Temozolomide
50 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

# Genetic test Affiliating Genes
1 Oligodendroglioma 29

Anatomical Context for Oligodendroglioma

MalaCards organs/tissues related to Oligodendroglioma:

41
Brain, Spinal Cord, Temporal Lobe, Bone, Bone Marrow, T Cells, Endothelial

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 727)
# Title Authors Year
1
Absence of 1p/19q codeletion in oligodendroglioma-like areas of pilocytic astrocytomas. ( 29595124 )
2018
2
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. ( 29131101 )
2018
3
Pre- and post-surgery MRSI predictive value in adult oligodendroglioma prognosis. ( 29902567 )
2018
4
Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. ( 29192869 )
2018
5
Malignant Melanoma Metastatic to Oligodendroglioma: Case Report and Literature Review of Tumor-to-Tumor Metastasis to Gliomas. ( 29746652 )
2018
6
Focal Cortical Dysplasia Type IIIb with Oligodendroglioma in a Seizure-Free Patient. ( 29429417 )
2018
7
Cerebellar Peduncle Localized Oligodendroglioma: A Case Report and Review of the Literature. ( 29438788 )
2018
8
Chronic Scalp Ulcer 35 Years after Skull Trepanation Surgery and Radiotherapy for Oligodendroglioma: A Further Example of Immunocompromised Cutaneous Districts. ( 29483982 )
2018
9
Enchondromatosis-associated oligodendroglioma: case report and literature review. ( 29224049 )
2018
10
Oligodendroglioma Cells Lack Glutamine Synthetase and Are Auxotrophic for Glutamine, but Do not Depend on Glutamine Anaplerosis for Growth. ( 29642388 )
2018
11
A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum? ( 29954769 )
2018
12
Holocord oligodendroglioma with intracranial extension in a young adult: a case report and review of literature. ( 29390865 )
2018
13
A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET. ( 29076897 )
2017
14
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
15
Diffuse Infiltrating Oligodendroglioma and Astrocytoma. ( 28640702 )
2017
16
Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma. ( 28900829 )
2017
17
MR textural analysis on T<sub>2</sub>FLAIR images for the prediction of true oligodendroglioma by the 2016 WHO genetic classification. ( 29140606 )
2017
18
A very rare spinal cord tumor primary spinal oligodendroglioma: A review of sixty cases in the literature. ( 29021677 )
2017
19
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. ( 28696020 )
2017
20
Vessel morphometric parameters-correlation with histologic grade and VEGF expression in oligodendroglioma. ( 28469969 )
2017
21
Multicentric high grade oligodendroglioma: a rare entity. ( 29078728 )
2017
22
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. ( 28498059 )
2017
23
Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. ( 28550371 )
2017
24
Characterization of brain tumours with spin-spin relaxation: pilot case study reveals unique T 2 distribution profiles of glioblastoma, oligodendroglioma and meningioma. ( 28894952 )
2017
25
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario. ( 28384867 )
2017
26
Cerebellar Cystic Oligodendroglioma in a Young Adult. ( 28694642 )
2017
27
Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. ( 28126746 )
2017
28
CNS cancer: Tracing stem cells in oligodendroglioma. ( 27874063 )
2017
29
Pinpointing Cancer Stem Cells in Oligodendroglioma. ( 27864226 )
2017
30
Genetic landscape of extreme responders with anaplastic oligodendroglioma. ( 28388591 )
2017
31
Pica in a Child with Anterior Cingulate Gyrus Oligodendroglioma: Case Report. ( 28704833 )
2017
32
IMAGING DIAGNOSIS -ANTEMORTEM DETECTION OF OLIGODENDROGLIOMA &amp;quot;CEREBROSPINAL FLUID DROP METASTASES&amp;quot; IN A DOG BY SERIAL MAGNETIC RESONANCE IMAGING. ( 28176389 )
2017
33
Osteosclerosis Secondary to Metastatic Oligodendroglioma. ( 28435646 )
2017
34
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. ( 28467778 )
2017
35
A Case of Congenital Brainstem Oligodendroglioma: Pathology Findings and Review of the Literature. ( 28815096 )
2017
36
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. ( 28472509 )
2017
37
Metastatic grade III oligodendroglioma revealed by refractory thrombocytopenia. ( 28737366 )
2017
38
Multimodal (18)F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. ( 28844925 )
2017
39
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. ( 27401158 )
2016
40
Granular cells in oligodendroglioma suggest a neoplastic change rather than a reactive phenomenon: case report with molecular characterisation. ( 27738816 )
2016
41
142a88Genetic and Nongenetic Determinants of Cellular Architecture in IDH1-Mutant Oligodendrogliomas and Astrocytomas Using Single-Cell Transcriptome Analysis. ( 27399421 )
2016
42
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
43
Application of diffusion-weighted imaging and dynamic susceptibility contrast perfusion-weighted imaging for ganglioglioma in adults: Comparison study with oligodendroglioma. ( 27502573 )
2016
44
Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. ( 27347150 )
2016
45
Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. ( 26771849 )
2016
46
IMAGING DIAGNOSIS-MAGNETIC RESONANCE IMAGING FEATURES OF A MULTIFOCAL OLIGODENDROGLIOMA IN THE SPINAL CORD AND BRAIN OF A DOG. ( 27490488 )
2016
47
Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma. ( 27862886 )
2016
48
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
49
Papilloedema secondary to oligodendroglioma. ( 27489047 )
2016
50
Imaging of oligodendroglioma. ( 26849038 )
2016

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
2 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112

Cosmic variations for Oligodendroglioma:

9
(show top 50) (show all 6845)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6959574 ZRSR2 central nervous system,brain,glioma,anaplastic c.260G>A p.R87K 23:15803744-15803744 5
2 COSM6959528 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 5
3 COSM5981027 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 5
4 COSM6912189 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 5
5 COSM2178900 VTCN1 central nervous system,brain,glioma,anaplastic c.404C>T p.S135F 1:117156615-117156615 5
6 COSM6969075 TSHR central nervous system,brain,glioma,anaplastic c.1493G>A p.G498D 14:81143551-81143551 5
7 COSM6969076 TSC2 central nervous system,brain,glioma,anaplastic c.3124C>T p.P1042S 16:2079189-2079189 5
8 COSM6946774 TSC2 central nervous system,brain,glioma,anaplastic c.574G>T p.D192Y 16:2055494-2055494 5
9 COSM6959458 TSC1 central nervous system,brain,glioma,anaplastic c.913+1G>A p.? 9:132912281-132912281 5
10 COSM10790 TP53 central nervous system,brain,glioma,anaplastic c.455C>T p.P152L 17:7675157-7675157 5
11 COSM44829 TP53 central nervous system,brain,glioma,anaplastic c.403T>G p.C135G 17:7675209-7675209 5
12 COSM11224 TP53 central nervous system,brain,glioma,anaplastic c.394A>C p.K132Q 17:7675218-7675218 5
13 COSM10659 TP53 central nervous system,brain,glioma,anaplastic c.817C>T p.R273C 17:7673803-7673803 5
14 COSM10648 TP53 central nervous system,brain,glioma,anaplastic c.524G>A p.R175H 17:7675088-7675088 5
15 COSM43599 TP53 central nervous system,brain,glioma,anaplastic c.607G>A p.V203M 17:7674924-7674924 5
16 COSM10672 TP53 central nervous system,brain,glioma,anaplastic c.577C>T p.H193Y 17:7674954-7674954 5
17 COSM44693 TP53 central nervous system,brain,glioma,anaplastic c.707A>C p.Y236S 17:7674256-7674256 5
18 COSM11133 TP53 central nervous system,brain,glioma,anaplastic c.725G>C p.C242S 17:7674238-7674238 5
19 COSM10663 TP53 central nervous system,brain,glioma,anaplastic c.916C>T p.R306* 17:7673704-7673704 5
20 COSM43697 TP53 central nervous system,brain,glioma,anaplastic c.832C>A p.P278T 17:7673788-7673788 5
21 COSM10768 TP53 central nervous system,brain,glioma,anaplastic c.535C>T p.H179Y 17:7675077-7675077 5
22 COSM43742 TP53 central nervous system,brain,glioma,anaplastic c.419C>T p.T140I 17:7675193-7675193 5
23 COSM44240 TP53 central nervous system,brain,glioma,anaplastic c.514G>T p.V172F 17:7675098-7675098 5
24 COSM44327 TP53 central nervous system,brain,glioma,anaplastic c.518T>C p.V173A 17:7675094-7675094 5
25 COSM10891 TP53 central nervous system,brain,glioma,anaplastic c.814G>A p.V272M 17:7673806-7673806 5
26 COSM46287 TP53 central nervous system,brain,glioma,anaplastic c.557A>G p.D186G 17:7675055-7675055 5
27 COSM10645 TP53 central nervous system,brain,glioma,anaplastic c.527G>T p.C176F 17:7675085-7675085 5
28 COSM10651 TP53 central nervous system,brain,glioma,anaplastic c.530C>G p.P177R 17:7675082-7675082 5
29 COSM43545 TP53 central nervous system,brain,glioma,anaplastic c.503A>G p.H168R 17:7675109-7675109 5
30 COSM10777 TP53 central nervous system,brain,glioma,anaplastic c.715A>G p.N239D 17:7674248-7674248 5
31 COSM44945 TP53 central nervous system,brain,glioma,anaplastic c.672G>C p.E224D 17:7674859-7674859 5
32 COSM11188 TP53 central nervous system,brain,glioma,anaplastic c.412G>C p.A138P 17:7675200-7675200 5
33 COSM10750 TP53 central nervous system,brain,glioma,anaplastic c.490A>T p.K164* 17:7675122-7675122 5
34 COSM10667 TP53 central nervous system,brain,glioma,anaplastic c.646G>A p.V216M 17:7674885-7674885 5
35 COSM6906 TP53 central nervous system,brain,glioma,anaplastic c.672+1G>A p.? 17:7674858-7674858 5
36 COSM43747 TP53 central nervous system,brain,glioma,anaplastic c.872A>G p.K291R 17:7673748-7673748 5
37 COSM43843 TP53 central nervous system,brain,glioma,anaplastic c.817C>G p.R273G 17:7673803-7673803 5
38 COSM10887 TP53 central nervous system,brain,glioma,anaplastic c.833C>G p.P278R 17:7673787-7673787 5
39 COSM43947 TP53 central nervous system,brain,glioma,anaplastic c.614A>G p.Y205C 17:7674917-7674917 5
40 COSM43753 TP53 central nervous system,brain,glioma,anaplastic c.560-1G>A p.? 17:7674972-7674972 5
41 COSM43846 TP53 central nervous system,brain,glioma,anaplastic c.487T>C p.Y163H 17:7675125-7675125 5
42 COSM44215 TP53 central nervous system,brain,glioma,anaplastic c.533A>C p.H178P 17:7675079-7675079 5
43 COSM11196 TP53 central nervous system,brain,glioma,anaplastic c.734G>T p.G245V 17:7674229-7674229 5
44 COSM43903 TP53 central nervous system,brain,glioma,anaplastic c.470T>G p.V157G 17:7675142-7675142 5
45 COSM44623 TP53 central nervous system,brain,glioma,anaplastic c.487T>A p.Y163N 17:7675125-7675125 5
46 COSM44633 TP53 central nervous system,brain,glioma,anaplastic c.583A>T p.I195F 17:7674948-7674948 5
47 COSM44910 TP53 central nervous system,brain,glioma,anaplastic c.403T>A p.C135S 17:7675209-7675209 5
48 COSM43743 TP53 central nervous system,brain,glioma,anaplastic c.914A>G p.K305R 17:7673706-7673706 5
49 COSM11451 TP53 central nervous system,brain,glioma,anaplastic c.672G>T p.E224D 17:7674859-7674859 5
50 COSM44570 TP53 central nervous system,brain,glioma,anaplastic c.332T>G p.L111R 17:7676037-7676037 5

Copy number variations for Oligodendroglioma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1 12.71 CDKN2A CDKN2B EGFR PDGFRA PTEN TP53
2
Show member pathways
12.66 CDKN2A CDKN2B EGFR PTEN TP53
3
Show member pathways
12.53 CDKN2A CDKN2B CDKN2C EGFR PDGFRA PTEN
4 12.49 ENO2 GFAP MBP NKX2-2 SYP
5 12.41 CDKN2A EGFR PDGFRA PTEN TP53
6 12.39 CDKN2A CDKN2C MGMT TP53 TP73
7
Show member pathways
12.29 CDKN2A PTEN TP53 TP73
8 12.27 CDKN2A CDKN2B CDKN2C TP53
9
Show member pathways
12.26 CDKN2A CDKN2B CDKN2C TP53
10 12.26 CDKN2A CDKN2B CDKN2C PDGFRA TP53
11 12.08 CDKN2A CDKN2B PTEN TP53
12 12.04 EGFR PDGFRA PTEN TP53
13 11.97 EGFR PTEN TP53 TP73
14 11.87 EGFR GFAP MBP TP53
15 11.84 CDKN2A PTEN TP53 TP73
16 11.77 CDKN2B PTEN TP53
17 11.74 GFAP MBP OLIG1 OLIG2
18 11.64 CDKN2A EGFR TP53
19 11.48 CDKN2A EGFR MGMT PDGFRA PTEN TP53
20 11.41 CDKN2B PTEN TP53
21 11.38 CDKN2A EGFR PDGFRA TP53
22 11.37 EGFR IDH1 PDGFRA PTEN TP53
23 11.06 CDKN2A CDKN2B CDKN2C TP53
24 11 GFAP NKX2-2 OLIG1 OLIG2 PDGFRA SYP
25
Show member pathways
10.92 CDKN2A TP53 TP73
26
Show member pathways
10.74 IDH1 IDH2

GO Terms for Oligodendroglioma

Cellular components related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 CDKN2A CDKN2B CDKN2C EGFR MBP MGMT

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.92 CDKN2A CDKN2B CDKN2C PTEN TP53
2 negative regulation of neuron differentiation GO:0045665 9.69 NKX2-2 OLIG2 TP73
3 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.65 CDKN2B CDKN2C PTEN
4 oligodendrocyte differentiation GO:0048709 9.58 CDKN2C OLIG1 OLIG2
5 replicative senescence GO:0090399 9.56 CDKN2A TP53
6 mitotic G1 DNA damage checkpoint GO:0031571 9.55 TP53 TP73
7 cell cycle arrest GO:0007050 9.55 CDKN2A CDKN2B CDKN2C TP53 TP73
8 negative regulation of telomerase activity GO:0051974 9.54 POT1 TP53
9 negative regulation of phosphorylation GO:0042326 9.5 CDKN2A CDKN2B CDKN2C
10 isocitrate metabolic process GO:0006102 9.49 IDH1 IDH2
11 spinal cord oligodendrocyte cell differentiation GO:0021529 9.46 NKX2-2 OLIG2
12 spinal cord oligodendrocyte cell fate specification GO:0021530 9.43 NKX2-2 OLIG2
13 positive regulation of oligodendrocyte differentiation GO:0048714 9.43 NKX2-2 OLIG2 TP73
14 glyoxylate cycle GO:0006097 9.37 IDH1 IDH2
15 response to organic cyclic compound GO:0014070 9.35 EGFR IDH1 MGMT NKX2-2 PTEN
16 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 8.92 CDKN2A CDKN2B CDKN2C PTEN

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 EGFR GFAP IDH1 PTEN SYP TP53
2 magnesium ion binding GO:0000287 9.67 ENO2 IDH1 IDH2 PTEN
3 isocitrate dehydrogenase activity GO:0004448 9.26 IDH1 IDH2
4 protein kinase binding GO:0019901 9.17 CDKN2A CDKN2B CDKN2C EGFR PTEN TP53
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH1 IDH2
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.13 CDKN2A CDKN2B CDKN2C

Sources for Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....